Reimagining Cancer Treatment

Syndax

Determined to realize a future in which people with cancer live longer and better than ever before

Q2 2016 CONFERENCE CALL
AUGUST 9, 2016

Forward-Looking Statements Disclosure

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding future results of the operations of Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company"), including financial position, strategy and plans, and Syndax's expectations for future operations, are forward-looking statements.

Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical site activation rates or clinical trial enrollment rates that are lower than expected, changes in expected or existing competition, failure of our collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Moreover, Syndax operates in a very competitive and rapidly changing environment. Other factors that may cause our actual results to differ from current expectations are discussed in Syndax's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. New risks emerge from time to time. It is not possible for Syndax's management to predict all risks, nor can Syndax assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied. Except as required by law, neither Syndax nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. Syndax undertakes no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in Syndax's expectations.

Reimagining Cancer Treatment

Syndax

Determined to realize a future in which people with cancer live longer and better than ever before

Company Strategy

Entinostat Breast Cancer

Entinostat Immuno-oncology

New molecules

Financing & Staffing

E2112

Phase 3 registration trial in advanced HR+, HER2- breast cancer patients

Exemestane +/- Entinostat

ECOG-ACRIN cancer research group
Reshaping the future of patient care



Treatment Cycle (28 days)

- Exemestane (25 mg): PO, days 1-28
- Entinostat/Placebo (5 mg): PO, d: 1, 8, 15, 22

Treatment cycles continue until disease progression or unacceptable toxicity

Enrollment has exceeded 50% of the accrual goal

Trial Highlights:

- FDA reviewed trial under SPA process
- Two primary endpoints: PFS and OS
- PFS readout is expected no sooner than 2H 2017
- Combination has been granted Breakthrough Therapy Designation by the FDA

ENCORE Clinical Trial Programs

- The ENCORE trials are designed to assess entinostat's ability to enhance checkpoint efficacy
- Entinostat-checkpoint inhibitor combination trials are expected to generate multiple milestones over the next 12 months

Entinostat-checkpoint combinations			Anticipated data presentation	
Trial	Partner	Indication	2H16	1H17
ENCORE 601	MERCK	NSCLC – PD(L)-1 naïve	Phase 1b RP2D	Phase 2; 1st Stage
		NSCLC – PD(L)-1 refractory		Phase 2; 1st Stage
		Melanoma		Phase 2; 1st Stage
ENCORE 602	Genentech A Member of the Roche Group	TNBC		Phase 1b safety, RP2D
ENCORE 603	MERCK Pfizer	Ovarian		Phase 1b safety

RP2D = Recommended Phase 2 Dose

ENCORE 601

First signal-seeking trial

KEYTRUDA® + Entinostat MERCK

Phase 1b:
open-label



Trial Milestones:

- Completed accrual for dose escalation stage (3mg and 5mg)
- Positive safety assessment made; 5mg dose progressed
- Dose confirmation safety assessment complete; Phase 2 screening initiated
- Phase 1b data presentation anticipated Q4 2016

ENCORE 601

First signal-seeking trial across 3 indications

KEYTRUDA® + Entinostat



Trial Milestones:

- Phase 2, Stage 1 is expected to begin Q3 2016
- Anticipate making go/no go decision to progress to Stage 2 in Q1 2017

ENCORE 602

Collaboration with another industry innovator

Tecentriq™ +/- Entinostat

Genentech
A Member of the Roche Group



Trial Centers

Primary: UCLA Health

CRO: Translational Research in Oncology Group **(TRIO)**

Primary Endpoints

- Phase 1b – Establish Phase 2 dose
- Phase 2 – PFS using RECIST 1.1

Secondary Endpoints

- ORR
- OS
- Safety & tolerability

Trial Milestones:

- Initiated Phase 1b dose determination stage in June 2016
- Phase 1b data presentation anticipated 1H 2017

CSF-1R regulates proliferation, survival, differentiation, and chemotaxis of mononuclear phagocytes

- CSF-1R is expressed on mononuclear phagocytic cells, including immunosuppressive TAMs
- Anti-CSF-1R Ab depletes TAMs and increases tumor infiltrating lymphocytes
  - Inhibition shows clinical activity in diffuse-type giant cell tumor
  - Preclinical synergistic anti-tumor activity seen with immune checkpoint inhibitors



MDSC – myeloid derived suppressor cell; TAM – tumor associated macrophage; Treg – regulatory T lymphocyte; CTL – cytotoxic T cell; ENT – entinostat; CSF-1R – colony stimulating factor -1 receptor

Source: data on file

Syndax anti-CSF-1R antibody properties

- SNDX-6352, developed at UCB as UCB6352
- High affinity, humanized IgG4P (K_D = 4-8 pM)
- Demonstrated binding to ligand binding domain; blocks CSF-1 and IL-34 binding
- Inhibits ligand induced monocyte activation
- No evidence of antibody mediated receptor internalization or activation
- IND-enabling studies completed by UCB



Source: data on file

Q2 Financial Position & Operating Results

Condensed Consolidate Balance Sheet Data as of 6/30/2016

- Cash, cash equivalents, and short-term investments of $125.5M
- Total common shares issued and outstanding 17,782,150
- Common stock and common stock equivalents 20,855,418

Condensed Consolidated Statement of Operations Data for the Three Months Ended 6/30/2016

- Net loss of $8.4M
- Net loss per share of $0.47 per share
- Non-cash stock-based comp of $0.8 M included in net loss

Summary Highlights

- Expanded pipeline with SNDX-6352
  - Clinical trials to be initiated Q4 2016
- ENCORE 601 Phase 1b safety assessment complete
  - Progression to Phase 2 in NSCLC and Melanoma at 5mg dose
  - Phase 2 screening initiated
  - Phase 1b abstract submitted for SITC, Q4 2016
- E2112 enrollment has exceeded 50% of the accrual goal
- ENCORE 602 for TNBC with Genentech initiated in June
- ENCORE 603 anticipated to commence in Q4 2016
- Pipeline funded through significant milestones

Thank you. Questions?

Syndax